Regeneron Pharmaceuticals, Inc.
REGN
$957.00
$19.392.07%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -0.08% | 4.39% | |||
| Total Other Revenue | 53.65% | 99.57% | |||
| Total Revenue | 2.13% | 6.48% | |||
| Cost of Revenue | 12.07% | 1.44% | |||
| Gross Profit | -5.99% | 10.98% | |||
| SG&A Expenses | 15.18% | -1.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.00% | 16.67% | |||
| Total Operating Expenses | 13.00% | 0.47% | |||
| Operating Income | -17.18% | 19.13% | |||
| Income Before Tax | 3.31% | 2.58% | |||
| Income Tax Expenses | -111.65% | -10.04% | |||
| Earnings from Continuing Operations | 15.06% | 4.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.06% | 4.07% | |||
| EBIT | -17.18% | 19.13% | |||
| EBITDA | -15.23% | 17.58% | |||
| EPS Basic | 14.74% | 4.75% | |||
| Normalized Basic EPS | -16.70% | 21.11% | |||
| EPS Diluted | 14.63% | 4.59% | |||
| Normalized Diluted EPS | -16.75% | 20.85% | |||
| Average Basic Shares Outstanding | 0.28% | -0.65% | |||
| Average Diluted Shares Outstanding | 0.35% | -0.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
